Written Authority Required Drugs

Hidradenitis Suppurativa

The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa (HS).

Treatment with adalimumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with moderate to severe HS.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing adalimumab.

Applications

Initial and recommencement of treatment

Make all initial and recommencement of treatment applications for authority approval to prescribe adalimumab for the treatment of moderate to severe HS in writing and:

All applications must include a completed:

Applications for balance of supply may be made by calling the PBS Complex Drugs Programs enquiry line.

Initial grandfather treatment

For patients who received non PBS subsidised adalimumab treatment for moderate to severe HS before 1 July 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

A patient may qualify for PBS subsidised adalimumab under the grandfather restriction once only.

Continuing treatment

Make all applications for continuing authority approval to prescribe adalimumab for the treatment of moderate to severe HS in writing and:

All applications must include a completed:

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

This information was printed Friday 24 May 2019 from https://www.humanservices.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/hidradenitis-suppurativa It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.humanservices.gov.au/individuals/site-notices when using this material.

Page last updated: 22 February 2019